



Advances in Molecular and Genetic Biomarkers in Head and Neck Squamous Cell Carcinoma

Guest Editors:

Prof. Dr. Joanna Katarzyna Strzelczyk

Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

Prof. Dr. Michal Masternak

1. Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA
2. Department of Head and Neck Surgery, Poznan University of Medical Sciences, Poznan, Poland

Deadline for manuscript submissions:

24 June 2025

Message from the Guest Editors

Dear Colleagues,

Head and Neck Squamous Cell Carcinoma (HNSCC) remains a significant oncological challenge due to its heterogeneity and complex molecular landscape. While research has identified diverse subtypes and neoplastic pathways in HNSCC, there's a critical need for specific and translatable molecular biomarkers for screening and diagnosis.

Recent advancements in analyzing DNA, RNA, and proteins offer unprecedented insights into HNSCC's molecular underpinnings. Identifying novel biomarkers associated with cancer development and progression is crucial for early detection and improved patient outcomes.

This special issue delves into the latest advancements in molecular and genetic biomarkers for HNSCC. We welcome high-quality original research and reviews focusing on multi-omics approaches (genomics, transcriptomics, proteomics) to unravel the fundamental mechanisms of HNSCC carcinogenesis, specially that explore novel biomarkers for early detection, risk stratification, and potential therapeutic targets.

We look forward to receiving your contributions.

Prof. Dr. Joanna Katarzyna Strzelczyk

Prof. Dr. Michal Masternak

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)